Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Orexigen Therapeutics to Present at Upcoming Investor Conferences

February 7, 2013

SAN DIEGO, Feb. 7, 2013 /PRNewswire/ — Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows:

    The 15th Annual BIO CEO & Investor Conference
    Date:                      Tuesday, February 12, 2013
    Time:                      2:00 p.m. Eastern Time
    Location:                  The Waldorf Astoria, New York

    2013 Leerink Swann Global Healthcare Conference
    Date:                      Wednesday, February 13, 2013
    Time:                      11:30 a.m. Eastern Time
    Location:                  The Waldorf Astoria, New York

The BIO CEO & Investor Conference presentation will be webcast live. To access the webcast, please visit the Investor Relations section of the company’s Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company’s other product candidate, Empatic(TM), has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.

Orexigen Contact:

McDavid Stilwell
VP, Corporate Communications and Business Development
(858) 875-8629

Media Contact:

Denise Powell
BrewLife
(510) 703-9491

SOURCE Orexigen Therapeutics, Inc.


Source: PR Newswire